Studien zu Lungenerkrankungen

Kurzbezeichnung Titel Prüfärzte Status
GO29527 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1-SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER PD Dr. Trummer Rekrutierung beendet
R2810-ONC-16111 1.A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), PLATINUM-BASED DOUBLET CHEMOTHERAPY, AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY), VERSUS PEMBROLIZUMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 ?50% (R2810-ONC-16111) Prof. Krauter in Vorbereitung
R2810-ONC-16113 2.A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), IPILIMUMAB (ANTI-CTLA-4 ANTIBODY), AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 <50% (R2810-ONC-16113) Prof. Krauter in Vorbereitung